Share price · LSTA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LSTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+17.6%
Nothing announced by LSTA that day or the session before.
- 21 Aug 2026+38.4%
- Day beforeEarnings date (period ending 2026-06-30)
- 28 Jul 2026-19.4%
Nothing announced by LSTA that day or the session before.
- 27 Jul 2026-13.8%
- 24 Jul 2026-21.2%
- 21 Jul 2026-36.5%
Nothing announced by LSTA that day or the session before.
- 13 Jul 2026+13.1%
Nothing announced by LSTA that day or the session before.
- 1 Jun 2026+10.2%
- 21 Apr 2026+12.4%
Nothing announced by LSTA that day or the session before.
- 20 Apr 2026-12.4%
Nothing announced by LSTA that day or the session before.
Share of unusual movement by asset
For each asset, the share of LSTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Alpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway)Peptide | Pancreatic Cancer | |
| Phase 2 | ANGPTL4Monoclonal antibody | Cardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $5.2M | $283M | $6.8M-$13M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $0.6M | $10M | $2.9M-$2.6M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $1.2M | $13M | $4.5M-$3.1M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $2.0M | $19M | $4.3M-$3.3M operating cash flow | report ↗ |
| 2025-Q2 | $0.1M | $2.3M | $17M+ $0.4M short-term inv. | $4.7M-$4.0M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $2.6M | $20M+ $2.8M short-term inv. | $4.7M-$5.4M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $2.5M | $20M+ $11M short-term inv. | $4.9M-$2.5M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $2.6M | $28M+ $5.5M short-term inv. | $5.0M-$5.3M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $3.2M | $22M+ $17M short-term inv. | $5.4M-$7.0M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.4M | $32M+ $19M short-term inv. | $5.3M-$3.6M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $3.2M | $24M+ $30M short-term inv. | $4.0M-$4.2M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $3.2M | $28M+ $27M short-term inv. | $6.2M-$8.2M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $3.4M | $31M+ $36M short-term inv. | $37M-$4.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.2M | $33M+ $36M short-term inv. | $6.6M-$5.1M operating cash flow | report ↗ |
| 2022-Q1 | — | $3.3M | $13M+ $74M short-term inv. | $4.2M-$5.6M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.1M | $13M+ $84M short-term inv. | $6.9M-$5.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.2M | $8.0M | $16M | $4.2M-$16M operating cash flow | report ↗ |
Lisata Therapeutics reported revenue of $0.17M for fiscal 2025, down 83.0% YoY, with R&D spend of $7.95M, down 29.8% YoY. The company held cash and equivalents of $15.96M and recorded a net loss of $16.59M, with quarterly net burn of $16.59M as reported.
The company’s narrative centers on its investigational product certepetide, including preliminary ASCEND trial data in metastatic pancreatic cancer, a completed BOLSTER trial in cholangiocarcinoma, and ongoing investigator-initiated trials. It also disclosed a proposed acquisition by Kuva Labs Inc. under a merger agreement dated March 6, 2026, with a tender offer of $5.00 per share plus a contingent value right of $1.00, expected to close in the second quarter of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $1.0M | $11M | $16M+ $9.4M short-term inv. | $5.0M-$19M operating cash flow | report ↗ |
| 2023-FY | $0 | $13M | $23M+ $22M short-term inv. | $5.2M-$20M operating cash flow | report ↗ |
| 2022-FY | $0 | $13M | $32M+ $33M short-term inv. | $14M-$21M operating cash flow | report ↗ |
| 2021-FY | — | $18M | $25M+ $67M short-term inv. | $6.9M-$22M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-01-09 | AZAB MOHAMMAD · director | Award / grant | 30,456 | — | — | Form 4 |
| 2026-01-09 | BROWN GREGORY B · director | Award / grant | 30,456 | — | — | Form 4 |
| 2026-01-09 | Flowers Cynthia Louise · director | Award / grant | 30,456 | — | — | Form 4 |
| 2026-01-09 | HENSON HEIDI · director | Award / grant | 30,456 | — | — | Form 4 |
| 2026-01-09 | KLOSK STEVEN M · director | Award / grant | 30,456 | — | — | Form 4 |
| 2026-01-09 | Buck Kristen K · EVP, R&D and CMO | Award / grant | 25,000 | — | — | Form 4 |
| 2026-01-09 | Imam Tariq · SVP, Bus Dev, General Counsel | Award / grant | 15,000 | — | — | Form 4 |
| 2026-01-09 | Nisco James · SVP, Fin/Treas, Chief Actg Off | Award / grant | 15,000 | — | — | Form 4 |